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OBJECTIVES: Chronic plantar fasciitis (CPF), the most
common cause of plantar heel pain, lacks an optimal treatment
standard. The electromagnetic Epos® Ultra (EPOS) and the elec-
trohydraulic OssaTron® (OSSA) are the only two FDA approved
extracorporeal shock wave therapy (ESWT) devices for CPF.
This assessment will examine the net health outcomes obtained
when using either of these devices in the treatment of CPF in
patients who failed to achieve satisfactory improvement with
initial conservative treatment. METHODS: Medline® MeSH
heading searches of published peer-reviewed clinical literature
identiﬁed all relevant studies that analyzed ESWT for the treat-
ment of CPF dating to 1996. Additionally, conferences of pro-
fessional organizations were searched for appropriate posters
and abstracts. Outcomes measures focused on the ability of the
comparators to reduce pain and the occurrence of adverse events.
RESULTS: Treatment with EPOS demonstrated pain relief as evi-
denced by visual analog scale (VAS) score improvement from
baseline and compared to control. When compared to control
group, VAS score improvement at 3 months post treatment with
ESWT was signiﬁcantly greater (p = 0.0149). When compared
to baseline VAS scores, the improvement seen at 3, 6, and 12
months post treatment was also signiﬁcantly greater (p < 0.05).
Adverse events in patients using EPOS were limited to pain at
the time of application, which resolved after the treatment was
completed. Treatment with OSSA resulted in greater pain relief
than placebo, revealing an improved VAS score of approximately
1.0 to 2.5 points. Minor adverse events appearing in the area
where the shock wave was applied were resolved within six
weeks. Studies also revealed that ESWT as a whole improved
patients’ mobility scores by 38–51% (p = 0.001) compared to
baseline. CONCLUSIONS: The results of this assessment
demonstrate that both EPOS and OSSA are safe and effective
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OBJECTIVE: Plantar fasciitis (PF), the most common cause of
plantar heel pain, affects middle-aged individuals and comprises
15% of overall foot-related complaints. Initial treatments for 
PF include non-steroidal anti-inﬂammatory drugs (NSAIDs),
custom foot orthotics and/or corticosteroid injections into the
heel. When symptoms persist beyond six months it is classiﬁed
as chronic PF (CPF); two options for treatment, surgical inter-
vention and extracorporeal shock wave therapy (ESWT), exist.
This analysis will determine the cost-effectiveness of ESWT in
relation to surgery for the treatment of CPF. METHODS: A
Markov model was constructed based on established manage-
ment practices for the treatment of CPF, simulating the distrib-
ution of patients into one of ﬁve health and treatment states.
Cost and probability values used to populate the model were
derived from appropriate Medicare reimbursement values, retail
and average wholesale prices and published peer-reviewed clini-
cal studies. Cost and effectiveness values were accumulated
monthly over a 12 month period, yielding incremental cost-
effectiveness ratios (ICERs) in dollars per quality-adjusted life
year ($/QALY). RESULTS: Model analysis reveals that surgery
has a lower overall cost of treatment ($1912 v. $2862 respec-
tively) and a higher overall effectiveness in comparison to ESWT
(0.6742 v. 0.5750 QALY respectively). Surgery dominates ESWT
due to its lower overall cost of treatment and higher effective-
ness value, resulting in a lower ICER as compared to ESWT
($2836/QALY v. $4977/QALY respectively). CONCLUSION:
Based on the results of this analysis, surgery is a more cost-
effective option than ESWT for the treatment of chronic plantar
fasciitis; however, the ICER of each of these methods fall 
below the commonly accepted willingness-to-pay threshold of
$50,000/QALY commonly used by payers for the adoption of
new technology. Therefore when surgery has failed, or is not an
option, ESWT remains a viable and cost-effective alternative.
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OBJECTIVES: The aim of the study is to compare the real hos-
pital cost with DRG reimbursement rate according to surgical
methods in patients with peritrochanteric fractures. METHODS:
Reimbursement data of the Hungarian Diagnosis Related
Groups derive from the ﬁnancial database of the National Health
Insurance Fund Administration. The real hospital costs data
were collected at the Traumatology Center of the University of
Pécs in 2003. We calculated the following cost elements: salaries
of the staff, implants, drugs, bandage, hotel (accommodation)
costs. The salaries and accommodation costs were calculeted for
one day from the administrative records of the University. Four
different surgical methods were included: Gamma nailing and
Dinamic Hip Screw (DHS) providing early weight bearing; Ender
nailing and ﬁx angled plate (FAP) osteosynthesis providing
gradual partial weigh bearing. The average Hungarian Forint
(HUF) vale of one DRG cost-weigh was 100,000HUF. The
exchanga rate: 1USD = 230HUF. RESULTS: The average DRG
cost-weights: 2.87 for DHS, Ender nailing and FAP osteosyn-
thesis, and 4.47 for Gamma nailing. The average accommoda-
tion cost was 13,276HUF/patient/day. The average cost of
wages: 19,985HUF/patient/day. Drug cost: 404HUF/day.
Implants: FAP: 21,300HUF; Ender nail: 3780HUF; DHS:
33,400HUF; Gamma nail: 55,400HUF. The number of average
length of stay was: Gamma nailing and DHS: 8 days, Ender
nailing 10 days, FAP osteosynthesis 13 days. Comparing the
DRG reimbursement with the calculated hospital cost we
received the further balance: Gamma nailing: +122,280HUF;
DHS: -15,720HUF; Ender nailing: -45,610HUF; FAP osteosyn-
thesis -171,685HUF. CONCLUSIONS: We can conclude that
DRG reimbursement exceed the real hospital costs in Gamma
nailing. The hospital costs of DHS, Ender nailing and FAP
osteosynthesis are higher than the DRG reimbursement therefore
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OBJECTIVES: This study aimed to investigate the effect of long
term persistent bisphosphonate usage on the risk for hospital-
ization due to osteoporotic fractures. METHODS: The
PHARMO database, which includes linked drug-dispensing
records and hospital discharge records for more than two million
subjects in deﬁned areas in the Netherlands, was used to iden-
tify new female users of alendronate, etidronate or risedronate
>50 years in the period January 1996–June 2003. Persistence
with bisphosphonate treatment was determined using the
method of Catalan. Within the cohort a matched case control
study was performed. Cases were selected on the basis of a ﬁrst
hospitalization for an osteoporotic fracture (index date). Con-
trols were matched 10 : 1 to cases on year of inclusion in the
cohort and were assigned a random index date. The association
with risk for fractures was assessed for persistent bisphospho-
nate use for one and two years prior to the index date. Analy-
ses were adjusted for differences in patient characteristics such
as age, previous hospitalization for fractures, co-morbidity and
co-medication. RESULTS: There were 14,760 new female users
of bisphosphonates were identiﬁed of which 541 women had a
hospitalization for osteoporotic fracture during follow-up. One-
year persistence rates improved with less frequent dosing (e.g.
33% with alendronate daily to 48% with alendronate weekly,
an increase of 15%). Similar results were obtained with rise-
dronate daily and weekly. One year persistent use of bisphos-
phonates resulted in a signiﬁcant 35% lower fracture rate (OR
0.74; 95%CI 0.57–0.95) whereas two year persistent use
resulted in a 47% lower rate (OR 0.68; 95%CI 0.47–0.96).
CONCLUSIONS: These results emphasize the importance of
persistent bisphosphonate usage to obtain the maximal protec-
tive effect of treatment. Persistence with bisphosphonates is
higher with less frequent dosing regimens but is still suboptimal.
This study has demonstrated that improving persistence results
in reduced hospitalization for osteoporotic fractures.
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OBJECTIVES: The aim of the study is to analyze the lethality
after femur neck fractures at different time. We analyze the
chance of lethality from the time of primary treatment of femoral
neck fracture at different time periods according to age-group,
sex and most frequently used surgical techniques. METHODS:
Data derive from the database of the National Health Insurance
Fund Administration and based on the ICD-10 S7200 code. The
bases of the evaluation are patients over 65 with femoral neck
fracture identiﬁed with Social Security Identiﬁcation Number
(TAJ) discharged from inpatient care institutions after primary
treatment. The following time periods were included into the
analysis: 0–30 days, 31–90 days, 91–180 days, 181–270 days,
271–360 days. The patients with polytrauma were excluded
from the study. Regarding surgical methods, the most frequently
used screw ﬁxation and arthroplasty were evaluated. Statistical
analysis means logistic regression and reference values were:
males, universities and arthroplasty. RESULTS: Altogether 4141
patients were included into the study. Female:male ratio was
23.71% : 76.29%. Sex: The female lethality was signiﬁcantly
lower than male in the ﬁrst half a year: in 0–30 days 0.527
(0.4398–0.6947), in 31–90 days 0.6156 (0.4897–0.7738), in
91–180 days 0.6378 (0.479–0.8491). Increasing age resulted in
a signiﬁcantly higher chance of lethality: 0–30 days 7.36%
1.0736 (1.0583–1.0891), 31–90 days 6.56% 1.0656
(1.0507–1.0807), 91–180 days 3.66% 1.0366 (1.0186–1.055),
181–270 days 3.96% 1.0396 (1.0168–1.0628), 271–360 days
2.93% 1.0293 (1.0053–1.0538). According to surgical
METHODS: arthroplasty 15.21%, screw ﬁxation: 69.72%.
Lethality after screw ﬁxation was signiﬁcantly higher in 0–30
days 1.9873 (1.366–2.9547) and 91–180 days 1.7168
(1.0931–2.6965). CONCLUSIONS: The chance of lethality
depending on age-group highlighted the importance of early
postoperative period. Higher age-groups, males and surgical
methods might have an effect at different level on mortality.
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OBJECTIVE: To estimate from a health plan perspective the
budget impact of treating postmenopausal women with bispho-
sphonates (alendronate, risedronate) to prevent hip and vertebral
fractures. METHODS: The annual budget impact was calculated
by estimating annual expenditures for bisphosphonate treatment
less the cost of hip or vertebral fractures prevented per year from
treatment. Data from pivotal clinical trials was used to estimate
the number of clinically signiﬁcant vertebral or hip fractures pre-
vented with bisphosphonates. Cost of a fracture was based on
medical claims data for women hospitalized for hip or vertebral
fractures from January 1, 2003–December 31, 2004. Medication
costs were based on average wholesale price for average dosing
of bisphosphonates ¥365 days, assuming 100% compliance with
therapy. RESULTS: Annual medication costs for treatment were
$9.9 million for risedronate and $10.3 million for alendronate
per 10,000 women. Annual savings from averted fractures per
10,000 women were $3.1–$3.8 million for high risk women and
$22,000–$33,000 for low risk women. The annual net budget
impact was $6.5–$6.8 million for high risk women and $9.8 to
$10.3 million for low risk women. Medication costs were about
three times higher in high risk women and 375 times higher in
low risk women than costs of hip or vertebral fractures pre-
vented. Limitations: As medication adherence is less than 100%
in practice, actual fracture prevention rates and medication costs
are likely to be less than the trial-based outcomes used for this
analysis. The analysis does not include quality of life, survival
impacts related to fractures, or cost impacts of treatment-related
adverse events. CONCLUSIONS: Using ideal assumptions for
baseline fracture risk and medication adherence, treatment costs
for bisphosphonates far exceed savings resulting from fractures
prevented. Postmenopausal women with high fracture risks show
the greatest beneﬁts and offsets in treatment costs.
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OBJECTIVES: To analyze the health insurance cost of medial
femoral neck fractures treated with arthroplasty, screw ﬁxation
and dynamic hip screw (DHS) methods on a 2 years follow up
